14531-47-6

Basic information

• Product Name: Bergenin pentaacetate
• Synonyms: Bergenin pentaacetate;Bergenin 3,4,8,10,11-pentaacetate
• CAS NO: 14531-47-6
• Molecular Formula: C24H26O14
• Molecular Weight: 538.45484
• Mol File: 14531-47-6.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Bergenin pentaacetate(CAS DataBase Reference)
• NIST Chemistry Reference: Bergenin pentaacetate(14531-47-6)
• EPA Substance Registry System: Bergenin pentaacetate(14531-47-6)

Safety Data

• Hazardous Substances Data: 14531-47-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Applications:
Bergenin pentaacetate is used as a therapeutic agent for the treatment of various diseases, including diabetes, cancer, and cardiovascular disorders. Its antioxidant and anti-inflammatory properties contribute to its potential efficacy in managing these conditions.
Used in Liver and Kidney Protection:
Bergenin pentaacetate is used as a protective agent for the liver and kidneys, as it has shown promising results in safeguarding these organs from damage caused by oxidative stress.
Used in Food Industry:
Bergenin pentaacetate is used as a natural preservative and food additive due to its antibacterial and antifungal properties, which can help maintain the quality and safety of food products.

Upstream product

• 477-90-7 bergenin 
• 75-36-5 acetyl chloride 
• 108-24-7 acetic anhydride 

Relevant articles and documents

The structure of bergenin.

X-ray analysis of the 3,4,8,10,11-penta-acetate (3) of bergenin has confirmed the earlier structural assignments.

Synthesis, pH dependent, plasma and enzymatic stability of bergenin prodrugs for potential use against rheumatoid arthritis

Bergenin is a unique C-glycoside natural product possessing anti-inflammatory and anti-arthritic activity. It is hydrophilic molecule and stable under acidic conditions however is unstable at neutral-basic pH conditions. The rate of degradation is directly proportional to the increase in pH which might be one of the reasons for its low oral bioavailability. Thus, herein our objective was to improve its stability using prodrug strategy. Various ester and ether prodrugs were synthesized and studied for lipophilicity, chemical stability and enzymatic hydrolysis in plasma/esterase. The stability of synthesized prodrugs was evaluated in buffers at different pH, in biorelevant media such as SGF, SIF, rat plasma and in esterase enzyme. All prodrugs displayed significantly improved lipophilicity compared with bergenin, which was in accordance with the criteria of drug-like compounds. Acetyl ester 4a2 appeared to be the most promising prodrug as it remained stable at gastric/intestinal pH and was completely transformed to the parent compound bergenin in plasma as desired for an ideal prodrug. The data presented herein, will help in designing stable prodrugs of unstable molecules with desired physicochemical properties in structurally similar chemotypes.

Practical Synthesis and Biological Evaluation of Bergenin Analogs

Here, we describe the practical synthesis and biological properties of bergenin and its structural analogs. Synthetic bergenin compounds were prepared by acylation of bergenin. These compounds were then evaluated for suppression of lipopolysaccharide-indu